 Connection
Michael Yaron to Antirheumatic Agents
This is a "connection" page, showing publications Michael Yaron has written about Antirheumatic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.308 |
|
|
|
-
Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sj?gren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis. 1999 Apr; 58(4):253-6.
Score: 0.138
-
Tishler M, Nyman J, Wahren M, Yaron M. Anti-Ro (SSA) antibodies in rheumatoid arthritis patients with gold-induced side effects. Rheumatol Int. 1997; 17(4):133-5.
Score: 0.118
-
Elkayam O, Yaron M, Zhukovsky G, Segal R, Caspi D. Toxicity profile of dual methotrexate combinations with gold, hydroxychloroquine, sulphasalazine and minocycline in rheumatoid arthritis patients. Rheumatol Int. 1997; 17(2):49-53.
Score: 0.029
-
Litinsky I, Paran D, Levartovsky D, Wigler I, Kaufman I, Yaron I, Yaron M, Caspi D, Elkayam O. The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine. 2006 Jan 21; 33(2):106-10.
Score: 0.014
-
Caspi D, Elkayam O, Eisinger M, Vardinon N, Yaron M, Burke M. Clinical significance of low titer anti-nuclear antibodies in early rheumatoid arthritis: implications on the presentation and long-term course of the disease. Rheumatol Int. 2001 Feb; 20(2):43-7.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|